The epigenetic function of androgen receptor in prostate cancer progression
Takahiro Sawada1,2, Yoshiaki Kanemoto1,2, Tomohiro Kurokawa1,2,3
1Graduate School of Life Science and Engineering, Iryo Sosei University, Fukushima, Japan.
Abstract:
Androgen and androgen deprivation (castration) therapies, including androgen receptor antagonists, are clinically used to treat patients with prostate cancer. However, most hormone-dependent prostate cancer patients progress into a malignant state with loss of hormone-dependency, known as castration (drug)-resistant prostate cancer (CRPC), after prolong androgen-based treatments. Even in the CRPC state with irreversible malignancy, androgen receptor (AR) expression is detectable. An epigenetic transition to CRPC induced by the action of AR-mediated androgen could be speculated in the patients with prostate cancer. Androgen receptors belongs to the nuclear receptor superfamily with 48 members in humans, and acts as a ligand-dependent transcriptional factor, leading to local chromatin reorganization for ligand-dependent gene regulation. In this review, we discussed the transcriptional/epigenetic regulatory functions of AR, with emphasis on the clinical applications of AR ligands, AR protein co-regulators, and AR RNA coregulator (enhancer RNA), especially in chromatin reorganization, in patients with prostate cancer.
Insights
Androgen receptor (AR) signaling drives prostate cancer progression, even in castration-resistant states. This review explores AR
Area of Science:
- Molecular Oncology
- Epigenetics
- Endocrinology
Background:
- Androgen deprivation therapy is a standard treatment for prostate cancer.
- Most patients develop castration (drug)-resistant prostate cancer (CRPC) despite treatment.
- Androgen receptor (AR) remains detectable and active in CRPC.
Purpose of the Study:
- To review the transcriptional and epigenetic regulatory roles of AR in prostate cancer.
- To highlight clinical applications of AR-targeting agents and coregulators.
- To emphasize AR's role in chromatin reorganization during prostate cancer progression.
Main Methods:
- Literature review of studies on AR function, epigenetics, and prostate cancer.
- Analysis of AR signaling pathways and their role in therapeutic resistance.
- Discussion of AR ligands, protein co-regulators, and enhancer RNAs.
Main Results:
- AR mediates gene regulation through ligand-dependent transcriptional activity.
- AR influences chromatin structure, contributing to epigenetic modifications.
- AR signaling persists in CRPC, driving tumor progression and malignancy.
Conclusions:
- AR plays a critical role in both hormone-dependent and castration-resistant prostate cancer.
- Epigenetic regulation by AR is a key factor in the transition to CRPC.
- Targeting AR pathways, including its coregulators and chromatin effects, offers therapeutic potential.
Related Concept Videos
Epigenetic Regulation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
The Ras Gene
Ras is a...
Testosterone: Functions and Regulation
Internal Receptors


